Protocol Ledger

NCT03627091 · Phase III · TERMINATED

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Interventional Phase III clinical trial protocol NCT03627091 sponsored by Takeda in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-06 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03627091
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03627091
Protocol FieldVerified Registry Value
NCT IdentifierNCT03627091
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2019-02-06
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI